Supreme Court of Canada Rules for Glaxo Smith Kline in Transfer-Pricing Case

, The Litigation Daily


The Supreme Court of Canada has brought some clarity to "transfer pricing"—an accounting method in which a multinational company charges for the products, IP licenses, and various services that it provides to a foreign subsidiary. On Thursday, in a win for Glaxo Smith Kline and its lawyers at Osler, Hoskin & Harcourt, the court ruled unanimously that the Canadian government had to take into account more than just the market price of a product when assessing whether a company's transfer pricing was reasonable.

This article has been archived, and is no longer available on this website.

View this content exclusively through LexisNexis® Here

Not a LexisNexis® Subscriber?

Subscribe Now

Why am I seeing this?

LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® customers will be able to access and use ALM's content by subscribing to the LexisNexis® services via® and Nexis®. This includes content from The National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM's other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.

ALM's content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.

For questions call 1-877-256-2472 or contact us at

What's being said

Comments are not moderated. To report offensive comments, click here.

Preparing comment abuse report for Article# 1202575746701

Thank you!

This article's comments will be reviewed.